Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study.

Andreassen, A K; Andersson, B; Gustafsson, F; Eiskjaer, H; Rådegran, G; Gude, E; Jansson, K; Solbu, D; Karason, K; Arora, S; Dellgren, G; Gullestad, L

Andreassen, A K; Andersson, B; Gustafsson, F; Eiskjaer, H; Rådegran, G; Gude, E; Jansson, K; Solbu, D; Karason, K; Arora, S; Dellgren, G; Gullestad, L.

Afiliación

Andreassen AK; Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Andersson B; Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Gustafsson F; Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
Eiskjaer H; Department of Cardiology, Aarhus University Hospital, Skejby, Denmark.
Rådegran G; Section for Heart Failure and Valvular Disease, Skåne University Hospital and Department of Clinical Sciences, Cardiology, Lund University, Lund, Sweden.
Gude E; Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Jansson K; Department of Cardiology, Heart and Medicine Center County Council of Ostergotland and Linkoping University, Linkoping, Sweden.
Solbu D; Novartis Norge AS, Oslo, Norway.
Karason K; Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Arora S; Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Dellgren G; Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden.
Gullestad L; Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.

Am J Transplant ; 16(4): 1238-47, 2016 Apr.

Article en En | MEDLINE | ID: mdl-26820618

Asunto(s)

Inhibidores de la Calcineurina/uso terapéutico; Everolimus/uso terapéutico; Rechazo de Injerto/prevención & control; Supervivencia de Injerto/efectos de los fármacos; Trasplante de Corazón; Inmunosupresores/uso terapéutico; Enfermedades Vasculares/tratamiento farmacológico; Adolescente; Adulto; Anciano; Aloinjertos; Ciclosporina/uso terapéutico; Femenino; Estudios de Seguimiento; Tasa de Filtración Glomerular; Rechazo de Injerto/diagnóstico; Rechazo de Injerto/etiología; Cardiopatías/cirugía; Humanos; Pruebas de Función Renal; Masculino; Persona de Mediana Edad; Complicaciones Posoperatorias; Pronóstico; Estudios Prospectivos; Factores de Riesgo; Receptores de Trasplantes; Enfermedades Vasculares/diagnóstico; Enfermedades Vasculares/etiología; Privación de Tratamiento; Adulto Joven

Palabras clave

cardiology, immunosuppression; clinical research; clinical trial modulation; heart transplantation; immune; immunosuppressant; mechanistic target of rapamycin (mTOR); mechanistic target of rapamycin: everolimus; practice

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Vasculares / Trasplante de Corazón / Inhibidores de la Calcineurina / Everolimus / Rechazo de Injerto / Supervivencia de Injerto / Inmunosupresores Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Transplant Asunto de la revista: TRANSPLANTE Año: 2016 Tipo del documento: Article País de afiliación: Noruega Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google